Breaking news: COVAXIN getting ready for nasal delivery

The COVAXIN vaccine developed by Bharath Biotech is now getting ready to try the nasal variant, which according to Dr. Gillurkar from a site chosen to monitor COVAXI vaccine efficacy. As COVAXIN is whole-virion inactivated, it targets all parts of the virus and makes it more effective.

Source: Gillurkar's Hospital- Facebook

The nasal variant in a Phase I and Phase II study will start at Dr. Gillurkar's Hospital in Nagpur, India. The injectable variant Phase I and Phase II studies were completed at this hospital. According to Dr. Gillurkar, "We are all set to host the trials for nasal Covaxine in next two weeks. Enough scientific evidences are available that vaccines given through nasal route are more effective than injected ones". 

The other advantages of nasal route are no brainer. It will drive the cost so far down that it may emerge as the most preferred. Let us all look forward to it.

Read more at:

http://timesofindia.indiatimes.com/articleshow/80127595.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst "


Also read:

https://www.msn.com/en-in/health/medical/covaxin-controversy-doctors-in-trial-sites-chosen-by-icmr-say-human-trials-cant-be-fast-forwarded-anticipate-6-month-observation-period/ar-BB16oNfo